This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Safety and Efficacy of MBI 226 2.5% and 5.0% Topical Acne Solutions in the Treatment of Acne

This study has been completed.
Information provided by:
BioWest Therapeutics Inc Identifier:
First received: September 13, 2005
Last updated: NA
Last verified: September 2005
History: No changes posted
This study investigates the safety and efficacy of MBI 226 2.5% and 5.0% Acne Solutions, applied topically for six weeks, in the treatment of acne.

Condition Intervention Phase
Acne Vulgaris Acne Propionibacterium Acnes Drug: MBI 226 Acne Solutions Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Phase II, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of MBI 226 2.5% and 5.0% Acne Solutions Applied Topically for 6 Weeks to Subjects With Acne Vulgaris

Resource links provided by NLM:

Further study details as provided by BioWest Therapeutics Inc:

Primary Outcome Measures:
  • - percent change in inflammatory, non-inflammatory, and total acne lesion counts over entire study and dichotomized Global Severity Assessment

Secondary Outcome Measures:
  • - percent change in lesion counts after ~2 and ~4 weeks
  • - Global Severity Assessment

Estimated Enrollment: 75
Study Start Date: October 2000
Estimated Study Completion Date: September 2001

Ages Eligible for Study:   13 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Males and females, ages 13 and up, exhibiting high levels of facial P. acnes
  • Presence of inflammatory and non-inflammatory lesions

Exclusion Criteria:

  • Acne conglobata, acne fulminans, or secondary acne (chlorine, drug-induced acne, etc.)
  • Active facial cysts
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00211523

Sponsors and Collaborators
BioWest Therapeutics Inc
Study Director: Jim Pankovich BioWest Therapeutics Inc
  More Information Identifier: NCT00211523     History of Changes
Other Study ID Numbers: A99004
Study First Received: September 13, 2005
Last Updated: September 13, 2005

Keywords provided by BioWest Therapeutics Inc:
acne vulgaris
MBI 226
Propionibacterium acnes
lesion counts

Additional relevant MeSH terms:
Acne Vulgaris
Acneiform Eruptions
Skin Diseases
Sebaceous Gland Diseases
Pharmaceutical Solutions
Antimicrobial Cationic Peptides
Anti-Infective Agents processed this record on September 20, 2017